Literature DB >> 7102257

Polymyositis--treatment and prognosis. A study of 107 patients.

K G Henriksson, P Sandstedt.   

Abstract

One hundred and seven patients with polymyositis or dermatomyositis were followed for an average of 5 years. In 100 patients it was possible to evaluate the effect of treatment with steroids or a combination of steroids and immunosuppressive drugs. Fifty patients improved, 50 did not. Compared with the treatment-resistant group the treatment-responsive patients were of younger age, did not have an associated malignancy or cardiac disease and began treatment within 24 months after the onset of muscular weakness. In the treatment-responsive group the degree of improvement was correlated to the mean dose of steroids given during the first 3 months of treatment. Eighty-seven per cent of surviving responsive patients had no or slight disability at the end of the investigation. The mortality rate was 23% and was highest in the treatment-resistant group. Comparison between different treatment programs was possible and based on the results, a treatment schedule could be recommended. The principles of this schedule are: During the first month high doses of prednisone or prednisolone should be given daily. From the second month, an alternate-day administration can be employed. Tapering to maintenance dose should be gradual and slow. The treatment period should be long. The mean duration in the present series was 27 months.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7102257     DOI: 10.1111/j.1600-0404.1982.tb03087.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  25 in total

1.  Prognosis and mortality of polymyositis and dermatomyositis patients.

Authors:  A Airio; H Kautiainen; M Hakala
Journal:  Clin Rheumatol       Date:  2006-02-14       Impact factor: 2.980

2.  Asymmetrical weakness in polymyositis associated with neuropathic involvement.

Authors:  M G Cohen; M S Schwartz; E K Li; R Kay
Journal:  Clin Rheumatol       Date:  1991-12       Impact factor: 2.980

3.  Polymyositis and cyclosporin A.

Authors:  J Alijotas; J Barquinero; J Ordi; M Vilardell
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

Review 4.  Polymyositis-dermatomyositis: a clinical review.

Authors:  K W Strauss; H Gonzalez-Buritica; M A Khamashta; G R Hughes
Journal:  Postgrad Med J       Date:  1989-07       Impact factor: 2.401

5.  Apparent haematuria: an early sign in polymyositis.

Authors:  R Lim; J L Parker
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-18

Review 6.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

7.  New application of myocardial antimyosin scintigraphy: diagnosis of myocardial disease in polymyositis.

Authors:  D Le Guludec; F Lhote; P Weinmann; I Royer; B Jarrousse; N Caillat-Vigneron; L Guillevin; J L Moretti
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

8.  High-dose intravenous human immunoglobulin in polymyositis resistant to treatment.

Authors:  S Jann; S Beretta; M Moggio; L Adobbati; G Pellegrini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-01       Impact factor: 10.154

9.  Muscle pain in neuromuscular disorders and primary fibromyalgia.

Authors:  K G Henriksson
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1988

10.  Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients.

Authors:  E T Koh; A Seow; B Ong; P Ratnagopal; H Tjia; H H Chng
Journal:  Ann Rheum Dis       Date:  1993-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.